Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tumor marker may guide chemo choice for rare cancers

NCT ID NCT03217097

Completed Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 116 people with advanced neuroendocrine tumors to see if a marker called MGMT can predict which chemotherapy works best. Researchers compared two chemo types—alkylating agents and oxaliplatin—based on MGMT status. The goal is to personalize treatment and improve response rates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE TUMORS

Contacts and locations

Locations

  • CH Annecy Genevois

    Pringy, 74374, France

  • CHU d'Angers

    Angers, 49933, France

  • Centre Oscar Lambret

    Lille, 59020, France

  • Hôpital Beaujon - APHP

    Clichy, 92118, France

  • Hôpital Claude Hurriet - CHRU Lille

    Lille, 59037, France

  • Hôpital Cochin - APHP

    Paris, 75014, France

  • Hôpital Edouard Herriot - Hospices Civils de Lyon

    Lyon, 69003, France

  • Hôpital Estaing, CHU de Clermont-Ferrand

    Clermont-Ferrand, 63003, France

  • Hôpital François Mitterrand - CHU Dijon Bourgogne

    Dijon, 21000, France

  • Hôpital Nord - CHU Saint Etienne

    Saint-Priest-en-Jarez, 42270, France

  • Hôpital Privé Jean Mermoz

    Lyon, 69008, France

  • Hôpital Rangueil - CHU Toulouse

    Toulouse, 31059, France

  • Hôpital Robert Debré - CHU Reims

    Reims, 51092, France

  • Hôpital Saint Louis - APHP

    Paris, 75010, France

  • Hôpital Sud - CHU Amiens

    Amiens, 80054, France

  • Hôpital Trousseau - CHU Tours

    Tours, 37044, France

  • Institut Gustave Roussy

    Villejuif, 94805, France

  • Institut Paoli Calmettes

    Marseille, 13009, France

  • Institut de Cancérologie de la Loire

    Saint-Priest-en-Jarez, 42270, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.